CLAIM CARD
The mechanistic evidence for PCSK9 inhibitors' effects on immune and inflammatory pathways is grounded in preclinical endothelial cell studies. This design directly tests the hypothesis that PCSK9 inhibition can attenuate inflammation at the cellular level. The study specifically investigated the mediating role of SIRT3, a mitochondrial deacetylase linked to longevity pathways. This preclinical approach provides a controlled mechanistic window into how PCSK9 inhibitors may modulate inflammatory responses independent of their lipid-lowering effects.
Evidence grade: exploratory
Contradiction status: none
Publication: 4753c82f-24d3-490c-8a23-6cc8d4194c24
Provenance: Derivation Web chain
Citation Support
source_1Ma 2025source_2Schwartz 2021source_3Lehrke 2024source_4Imran 2023source_5Faraidy 2023